Despite Advances in RNAi Rxs, Merck Exec Says Field Has Many Issues to Overcome

Speaking at this year’s Drug Information Association Oligonucleotide-based Therapeutics Conference, Merck Research Laboratories Alan Sachs told attendees that key issues involving efficacy, safety, and delivery — the “number one problem” — must be addressed before the RNAi therapeutics field can succeed.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.